Compare DLPN & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | SCNX |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Other Pharmaceuticals |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 16.2M |
| IPO Year | 2008 | 2019 |
| Metric | DLPN | SCNX |
|---|---|---|
| Price | $1.09 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 6.3K | ★ 299.3K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.87 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $56,699,389.00 | $3,831,778.00 |
| Revenue This Year | $14.73 | $1,097.38 |
| Revenue Next Year | $7.41 | $239.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 9.70 | ★ 30.72 |
| 52 Week Low | $1.02 | $0.24 |
| 52 Week High | $1.88 | $2.60 |
| Indicator | DLPN | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 27.72 |
| Support Level | $1.06 | $0.30 |
| Resistance Level | $1.20 | $0.43 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 29.37 | 1.65 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing, and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials. The company operates within the U.S.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.